This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (45)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Aciclovir and Vidarabine Therapy

Deborah Pavan-Langston, MD; No Hee Park, DDS, PhD; Jonathan H. Lass, MD

Arch Ophthalmol. 1979;97(8):1508-1510.

Abstract
• This study reports the therapeutic efficacy of systemic antiviral drugs in reducing the incidence of trigeminal ganglionic latent herpes simplex virus (HSV) after ocular infection in mice. Aciclovir sodium, 60 mg/kg daily for five days starting three and 24 hours after inoculation, resulted in a significant decrease in recovery of latent HSV, 28% and 54% positive, respectively, in comparison to untreated controls, 100% positive. Initiation of similar therapy three weeks after inoculation for 5, 10, and 15 days resulted in progressive decrease in persistence of latent virus, being 100%, 33%, and 12% positive, respectively. Systemic vidarabine, 50 mg/kg daily for 15 days starting three weeks after inoculation, also resulted in a significant decrease of positive ganglionic cultures (60% positive) in comparison to the untreated controls. The results indicate that replication of HSV in the trigeminal ganglia in mice is probably continuous and that this reservoir of recurrent ocular herpes is amenable to therapy with systemic antiviral agents.

Author Affiliations
From the Department of Cornea Research, Eye Research Institute of Retina Foundation, and Department of Ophthalmology, Harvard Medical School, Boston.

Footnotes
Accepted for publication Feb 20, 1979.

Reprint requests to Department of Cornea Research, Eye Research Institute of Retina Foundation, 20 Staniford St, Boston, MA 02114 (Dr Pavan-Langston).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Famciclovir and Valaciclovir Differ in the Prevention of Herpes Simplex Virus Type 1 Latency in Mice: a Quantitative Study
Thackray and Field
Antimicrob. Agents Chemother. 1998;42:1555-1562.
ABSTRACT | FULL TEXT  

Prognostic Indicators of Herpetic Keratitis: Analysis of a Five-Year Observation Period After Corneal Ulceration
Wilhelmus et al.
Arch Ophthalmol 1981;99:1578-1582.
ABSTRACT  

Ganglionic Herpes Simplex and Systemic Acyclovir
Pavan-Langston et al.
Arch Ophthalmol 1981;99:1417-1419.
ABSTRACT  

Acyclovir Therapy for the Orofacial and Ganglionic HSV Infection in Hairless Mice
Park et al.
JDR 1980;59:2080-2086.
ABSTRACT  

Acyclovir Topical Therapy of Cutaneous Herpes Simplex Virus Infection in Guinea Pigs
Park et al.
Arch Dermatol 1980;116:672-675.
ABSTRACT